"Ascent-03" / GS-US-592-6238

Topic of Study: Breast Cancer

Sponsor: Genentech, Inc.

Principal Investigator: David A. Riseberg, M.D., 410-783-5858

Research Coordinator: Alexandra Cline, RN, 410-951-7956; Shannon Householder, RN, 410-951-7908; Sarah Orndorff, RN 410-332-9459

Coordinated Through: Institutional Research

This is a randomized, open-label, Phase 3 study of Sacituzumab Govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with Anti-PD-(L)1 Agents in the early setting whose tumors do express PD-L1. (Clinicaltrials.gov ID#: NCT05382299)